Latest news with #HematopoieticStemCell
Qatar Tribune
03-06-2025
- General
- Qatar Tribune
Spotlight on SidraMedicine's Stem Cell Transplant Ward
Tribune News Network Doha The new Paediatric Hematopoietic Stem Cell Transplant (HSCT) Ward at Sidra Medicine represents a major advancement in its commitment to deliver state-of-the-art, lifesaving care for children with cancer, blood disorders, immune deficiencies, and other complex conditions. As part of Sidra Medicine's comprehensive Paediatric Hematology—Oncology, and HSCT Programme, the ward is uniquely equipped to provide curative therapy through cellular and gene-based treatment approaches. This initiative positions Sidra Medicine as a national and regional leader in paediatric stem cell transplantation and personalized medicine. 1. What is the purpose of the new paediatric HSCT Ward at Sidra Medicine? The new paediatric HSCT Ward is designed to treat children with life-threatening cancer, blood, immune, and genetic disorders. It is a core part of Sidra Medicine's HSCT Programme using curative therapy to provide life-saving treatment for children. is HSCT and how does it work? HSCT (Hematopoietic Stem Cell Transplantation), also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). It is currently the only curative treatment for many congenital and acquired otherwise fatal and acquired fatal paediatric diseases. The procedure is at the forefront of personalised medicine and plays a vital role in the development of advanced cell and gene therapies. 3. Why is the paediatric HSCT ward being opened? To address the growing demand for paediatric transplant services, eliminate the need for families to travel abroad, and enhance our national capability in advanced cellular therapy. conditions will be treated at theHSCT Ward? The HSCT ward will serve paediatric patients with a range of malignant and non-malignant conditions, including leukemia, lymphoma, solid tumours, thalassemia, sickle cell disease, primary immune deficiencies, metabolic diseases, and certain autoimmune and genetic disorders. many beds are in the HSCT Ward? The paediatric hematology-oncology and HSCT Ward has a 20-bed capacity. It is divided into two main sections: One section is dedicated to pediatric patients undergoing HSCT (bone marrow transplant), and the other for patients with complex hemato-oncology diagnoses, such as paediatric cancer, who are receiving chemotherapy or inpatient care for treatment-related complications. Note that HSCT is a medical—not surgical—procedure, and no surgeries take place in the HSCT ward. will the paediatric HSCT ward open? The paediatric HSCT ward is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants at a later stage. is eligible for treatment? The ward is exclusively for paediatric patients under the age of 18. It serves both local and international patients in need of HSCT or inpatient hematology-oncology care. is the HSCT Programme about? The HSCT programme at Sidra Medicine is part of a precision medicine strategy to treat patients with various blood diseases and cancers including sickle cell disease, thalassemia, leukemia, lymphoma, solid tumors. In addition, the programme includes the treatment of primary immune deficiencies, metabolic diseases, and certain genetic and autoimmune disorders. makes this programme unique in Qatar? This is the first dedicated paediatric HSCT programme in the country, reducing the need for children to travel abroad for transplant services. The programme also integrates cutting-edge research, cell therapy, and gene therapy capabilities. 10. What are the safety and infection control measures in place? The unit adheres to the highest international infection control standards, including high-level HEPA-filtered, positive pressure isolation rooms to protect patients during the vulnerable aplasia period when the immune system is suppressed. 11. How many children are currently awaiting HSCT in Qatar? More than 50 children are currently on the transplant waitlist, highlighting the urgent need for this new facility. Sidra Medicine treat international patients? Yes, our services are open to eligible international paediatric patients and align with our vision to be a regional centre of excellence in paediatric cell and gene therapy.
Yahoo
11-02-2025
- Business
- Yahoo
ADIA Nutrition Inc. Identifies Historical Share Issuance Issues; Commits to Retiring over 25 Million Shares
Winter Park, Florida--(Newsfile Corp. - February 11, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in health and wellness solutions, has uncovered issues with share issuance from over a decade ago. Following an internal review, it was discovered that around 25 million shares were either issued or committed without proper documentation. This includes 15 million shares currently outstanding and 10 million shares promised in an agreement to pay, prior to the current board's tenure. ADIA Nutrition is now actively working to retire these shares which would decrease the current number of outstanding shares by approximately 15 percent. OTC MarketsTo view an enhanced version of this graphic, please visit: ADIA's Current Share Structure (as recorded by OTC Markets): Outstanding: 95,899,861 Restricted: 74,051,080 Unrestricted: 21,848,781 Held at DTC: 19,575,347 Float: 13,848,781 The company's accountants and board are also examining other outstanding restricted shares that might have been improperly issued before the current board assumed control. After a detailed review of its shareholder structure, ADIA Nutrition confirmed that these shares lacked the required legal documentation and regulatory filings. Larry Powalisz, CEO of ADIA Nutrition Inc., commented, "We have taken immediate steps to correct this past oversight. Ensuring the integrity and legality of our share structure is crucial for our commitment to transparency. We are collaborating closely with our legal advisors to retire these shares appropriately." Steps Being Taken Include: Investigation: A comprehensive review of historical records to understand how the undocumented issuance occurred. Compliance: Working with legal experts to ensure all share retirement complies with regulatory requirements. Transparency: Engaging in direct communication with shareholders to keep them informed about the actions being taken. This initiative will not impact ADIA Nutrition's operational capabilities or its strategic focus on health and wellness. The company continues its commitment to innovation in areas like umbilical cord stem cell treatments and Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis. For media inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in Hematopoietic Stem Cell Transplantation (HSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
